Ads
related to: eau guidelines prostate cancer 2024 statistics- Oral Medication
Learn More About An Oral Treatment
For Metastatic Prostate Cancer.
- Side Effect Information
Learn More About Potential Side
Effects And Safety Information.
- Genomic Testing
Read How Testing Could
Help Inform Your Treatment Plan.
- Patient Support Program
Learn About A Treatment Option
And Patient Support.
- Oral Medication
Search results
Results From The WOW.Com Content Network
In a separate study of men from the pre prostate cancer screening era managed with watchful waiting (56% over age 70 years), progression to distant metastasis or prostate cancer death was 13.9% and 12.3%, respectively for Gleason score 6 or below, but considerably higher at 18.2 and 22.7%, 30% and 20%, 44.4% and 55.6% for Gleason 3+4, 4+3, and ...
An additional example of EAU collaboration with another organisation for the benefit of urology is the World Health Organization (WHO) Consensus Conference on bladder cancer, which was held in April 2008. The European Association of Urology Nurses (EAUN) aims to contribute to the development of higher standards of urology nursing in Europe.
A 2024 overview of reviews published in Seminars of Nuclear Medicine concluded that while evidence gaps remain for some outcomes and most systematic reviews are at high or unclear risk of bias, the evidence base is broadly supportive of 18-F PSMA PET/CT in patients with high-risk prostate cancer or biochemical recurrence [10]
Prostate cancer is a major topic of ongoing research. From 2016 to 2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [122] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost ...
The American Urological Association (AUA) guidelines for the treatment of BPH from 2018 stated that TUMT may be offered to patients provided they are informed that it is associated with a higher risk of necessary retreatment compared to TURP. [6] The European Association of Urology (EAU) has – as of 2019 – removed TUMT from its guidelines. [7]
It is the official journal of the European Association of Urology. The editor-in-chief is James Catto of the University of Sheffield . According to the Journal Citation Reports , the journal has a 2022 impact factor of 23.4.